AI assistant
Active Biotech — AGM Information 2010
May 7, 2010
3133_rns_2010-05-07_d9004ac2-db5a-4679-a75c-e1fbdf7926f0.pdf
AGM Information
Open in viewerOpens in your device viewer
PRESS RELEASE
Annual General Meeting of Active Biotech AB
The Annual General Meeting of Active Biotech was held on May 6, 2010.
In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid.
In accordance with the Election Committee's proposal, the Board members Mats Arnhög, Klas Kärre, Tomas Nicolin, Magnhild Sandberg, Peter Sjöstrand and Peter Ström were re-elected. The Meeting also resolved to re-elect Mats Arnhög as Chairman of the Board.
Furthermore, in accordance with the Election Committee's proposal, the Meeting resolved that the Election Committee shall be composed of representatives for the three largest owners, as per end of September, 2010, as well as the Chairman of the Board.
The Meeting approved the Board's proposal concerning guidelines for remuneration to the President and other senior executives. The guidelines essentially conform to the principles applied to date.
Finally, in accordance with the Board's proposal, the Meeting resolved to authorize the Board, for a period that does not extend past the date of the next Annual General Meeting, to resolve on the issue of not more than six million new shares and/or convertibles with the corresponding dilution effect, with or without pre-emptive rights for the company's shareholders.
Lund, May 7, 2010
Active Biotech AB (publ)
Tomas Leanderson President and CEO
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex™ for RA. Please visit www.activebiotech.com for more information.
Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08:30 am CET on May 7, 2010.
Active Biotech AB (org. no. 556223-9227) P.O. Box 724, SE-220 07 Lund, Sweden Tel +46 46-19 20 00 Fax +46 46-19 11 00
www.activebiotech.com